Company / SG&A Expense
Bausch & Lomb Corp SG&A Expense History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$2.2B
FY2025
5-year range
$1.4B / $2.2B
FY2021-FY2025
Trend
+7.3%
vs FY2024
Sector context
#23 of 152
Health Care
What the data says
Bausch & Lomb Corp's sg&a expense of $2.2B is higher than 85% of companies in the Health Care sector (FY2025). SG&A Expense has increased for 5 consecutive years, from $1.3B in FY2020 to $2.2B in FY2025.
Based on SEC 10-K filings.
$2.2B in FY2025 with a 5-year CAGR of +12.3%. Top quartile in the Health Care sector.
Increased from $1.7B to $2.2B over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +14.8%
- 5-Year CAGR
- +12.3%
- 10-Year CAGR
- -
Sector benchmark
Bottom 15% in Health CareTop 85% of 152This company $2.2B Sector average $182.7B
▼
-98.8% below sector average
Key checks
Key Insights
- Bausch & Lomb Corp's sg&a expense has grown for 5 consecutive years.
- 5-year CAGR of +12.3%, indicating consistent growth.
- In FY2025, sg&a expense increased 7.3% year-over-year.
- Ranks #23 out of 152 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 0.74 (distress zone, below 1.8 threshold)
- Negative profit margin: -6.6%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.2B | +7.3% |
| FY2024 | $2.1B | +19.9% |
| FY2023 | $1.7B | +17.5% |
| FY2022 | $1.5B | +6.4% |
| FY2021 | $1.4B | +10.9% |
| FY2020 | $1.3B | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026